Ixekizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1344 publications

Interleukin-17A inhibitors for guttate psoriasis treatment: A retrospective cohort study.

Interleukin-17A inhibitors for guttate psoriasis treatment: A retrospective cohort study.

Journal: JAAD international

Published: April 13, 2026

Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature.

Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature.

Journal: Journal of drugs in dermatology : JDD

Published: April 03, 2026

Commentary on: "Ixekizumab with Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity".

Commentary on: "Ixekizumab with Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity".

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 31, 2026

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.

Journal: Proceedings (Baylor University. Medical Center)

Published: March 16, 2026

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

Journal: Expert opinion on pharmacotherapy

Published: March 14, 2026

Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexity.

Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexity.

Journal: Cureus

Published: March 02, 2026

Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings.

Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings.

Journal: Dermatology and therapy

Published: February 17, 2026

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: February 09, 2026

IL-17A Inhibitors Therapy Affect Oral Fungal and Bacterial Microbiome in Psoriasis.

IL-17A Inhibitors Therapy Affect Oral Fungal and Bacterial Microbiome in Psoriasis.

Journal: Experimental dermatology

Published: February 05, 2026

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 03, 2026

Severe Hidradenitis Suppurativa and Subsequent Myelodysplastic Syndrome: A Case Report Highlighting Chronic Inflammatory Burden and Carcinogenic Risk.

Severe Hidradenitis Suppurativa and Subsequent Myelodysplastic Syndrome: A Case Report Highlighting Chronic Inflammatory Burden and Carcinogenic Risk.

Journal: Cureus

Published: February 02, 2026

Biological Treatment of Psoriasis-Data So Far.

Biological Treatment of Psoriasis-Data So Far.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 26, 2026

Showing 1-12 of 1,344

Last Updated: 04/28/2026